Læknaneminn - 01.04.1997, Side 132

Peter Duesberg and David Rasnick
1996; 111-125.
32. Craddock M. HIV: Science by press conference, in AIDS: virus- or
drug induced?, (eds.) Kluwer, Dordrecht, Netherland, 1996; 127-
130.
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM,
Markowitz M. Rapid Turnover of Plasma Virions and CD4
Lymphocytes in HIV-1 Infection. Nature 1995; 373: 123-126.
34. Maddox J. Duesberg and the new view of HIV. Nature 1995; 373:
189.
35. Duesberg P, Horton R. “The AIDS Heresy”: an exchange. The New
York Review 1996; 43: 51, August 8.
36. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma
among persons with AIDS: a sexually transmitted infection? Lancet
1990; 335: 123-128.
37. Haverkos HW, Drotman DP, Hanson D. Surveillance for AIDS-
related Kaposi’s sarcoma (KS): update. NIDA/CDC, Rockville,
MD/Atlanta, GA 1994; May.
38. Duesberg P. Commentary: non-HIV hypotheses must be studied
more carefully. BMJ 1996;312:210-211.
39. Lockemann U, Wischhusen F, Pueschel K, et al. Vergleich der HIV-
1-Praevalenz bei Drogentodesfaellen in Deutschland sowie in ver-
schiedenen europaeischen Grosstaedten (Stand: 31. 12. 1993). AIDS
Forschung 1995; 10: 253-256.
40. Brettle RP. Clinical features of drug use and drug use related to HIV.
IntJSTD&AIDS 1996; 7: 151-165.
41. Hayes T, Altman R, Akili-Obika A, Buehler JW, Costa SJ, Beil JK,
Moore LG, Massey JW, Williams NM. HlV-related deaths from
selected infectious diseases among persons without AIDS in New
Jersey. Journal of Acquired Immune Deficiency Syndromes 1994; 7:
1074-1078.
42. Kitange HM, Machibya H, Black J, Mtasiwa DM, Masuki G,
Whiting D, Unwin N, Moshiro C, Klima PM, Lewanga M, Alberti
KGMM, McLarty D, for adult morbidity and mortality project.
Outlook for survivors of childhood in sub-Saharan Africa: adult mor-
tality in Tanzania. BMJ 1996; 312: 216-220.
43. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk
of human immunodeficiency virus transmission from heterosexual
adults with transfusion-associated infections. JAMA 1988; 259: 55-
58.
44. Jacquez JA, Koopman JS, Simon CP, Longini Jr. IM. Role of the pri-
mary infection in epidemics of HIV infection in gay chorts. J
Acquired Immune Deficiency Syndromes 1994; 7: 1169-1184.
45. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan
MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O’Neill
E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J,
Stratton P, Balsley J, Pediatric AIDS Clinical Trials Group Protocol
076 Study Group. Reduction of Maternal-Infant Transmission of
Human Immunodeficiency Virus Type 1 With Zidovudine
Treatment. N ew Engl J Med 1994; 331: 1173-1180.
46. Duesberg PH. Retroviruses as carcinogens and pathogens: expecta-
tions and reality. Cancer Res 1987; 47: 1199-1220.
47. Duesberg PH. HIV and AIDS. Science 1993; 260: 1705.
48. Duesberg PH. The HIV gap in national AIDS statistics.
Biotechnology 1993; 11: 955-956.
49. Cone RW, Hackman RC, Huang M-LW, Bowden RA, Meyers JD,
Metcalf M, Zeh J, Ashley R, Corey L. Human herpesvirus 6 in lung
tissue from patients with pneumonia after bone marrow transplanta-
tion. N EnglJMed 1993; 329: 156-161.
50. Mims C, White DO. Viral Pathogenesis and Immunology. Blackwell
Scientific Publications, Oxford, 1984.
51. Drug Strategies. Keeping score; What We Are Getting for Our
Federal Drug Control Dollars. Drug Strategies, Washington DC,
1995.
52. Bureau of Justice Statistics. Drugs, crime, and the justice system.
U.S. Dept. of Justice, Washington DC, 1992.
53. Clinton W, The White House. The National Drug Control Strategy:
1996. The White House, Washington DC, 1996.
54. Courtwright DT. Dark Paradise: opiate addiction in America before
1940. Harvard University Press, Cambridge, MA, 1982.
55. Jonnes J. Hep-cats, narcs, and pipe dreams. Scribner, New York,
1996.
56. Haverkos HW, Dougherty J. Health hazards of nitrite inhalants. Am
J Med 1988; 84: 479-482.
57. Siegel R. New pattenrs of cocaine use: changing doses and routes, in
Cocaine use in America: epidemiologic and clinical perspectives, N.
Kozel and E. Adams (eds.) NIDA Research Monographs, Washington
DC, 1985;
58. Schuster C. Cocaine use in America: epidemiological and clinical per-
spectives, in NIDA Research Monograph Series, NIDA US
Department HHS (eds.) US Dept. HHS, 1985; v.
59. Kozel NJ, Adams EH. Epidemiology of drug abuse: An overview.
Science 1986; 234: 970-974.
60. Meddis SV. Heroin use said to near crisis level. USA Today
(Arlington) 1994: 1, 3A, May 25.
61. U.S. Department of Health & Human Services. Annual Medical
Examiner data. Data from the Drug Abuse Warning Network
(DAWN) 1994; 1-82, 1994.
62. Office of National Drug Control Policy. Drugs & Crime Data.
Drugs & Crime Clearinghouse 1996; July 1996.
63. Perlman D. Cocaine Emergencies Hit Record. SF Chronicle (San
Francisco) 1996: Al, A9, May 1.
64. Bureau of Justice Statistics (eds.) Catalog of Federal Publications on
Illegal Drug and Alcohol Abuse (1991), U.S. Department of Justice,
Washington D.C., .
65. Flanagan TJ, Maguire K. Sourcebook of Criminal Justice Statistics
(1989)—Bureau of Justice Statistics NCJ-124224. U.S. Department
of Justice, U.S. Government Printing Office, Washington, DC, 1989.
66. Anderson W. Drug Smuggling. U. S. General Accounting Office,
Washington, DC, 1987.
67. Schnoll SH, Karrigan J, Kitchen SB, Daghestani A, Hansen T.
Characteristics of cocaine abusers presenting for treatment, in
Cocaine use in America: epidemiologic and clinical perspectives,
NIDA US Dept. HHS (eds.) US Dept. HHS, 1985; 171-181.
68. Gettman J. Heroin Returning to Center Stage. High Times 1994;
23, December.
69. Smith RJ. U.S. Is Losing War on Drugs, Analysts Say. San Francisco
Chronicle (SF) 1995: Al, A9, July 10.
70. Evenson L, Whiting S. Heroin’s in Fashion—and Death Statistics
Prove It. San Francisco Chronicle (San Francisco) 1996: A1-A8, Jul
30.
71. Sadownick D. Kneeling at the Crystal Cathedral. Genre 1994; 40-
45, 86-90, December/January 1994.
72. Rotello G. A deal with the devil. The Advocate 1996; 96, October,
15.
73. Russell S. ‘Speed’ Hospitalizations Soar. SF Chronicle (San
Francisco) 1996: A13, A15, July 2.
74. Drug Strategies. Keeping Score. Keeping Score 1996; 1-33.
75. Wallace B. ‘Speed’Abusers Need More and More. SF Chronicle (San
Francisco) 1996: A2, May 31.
76. Mann C. Poppers ... high time to think again. Continuum 1995; 3:
10,
77. Young I. Hell Bent ... or Heavenly Scent? Continuum 1995; 3: 22-
25,
78. Bethell T. AIDS and Poppers, in AIDS: Virus- or Drug Induced?, P.
Duesberg (eds.) Kluwer Academic Publishers, Dordrecht, 1996; 315-
323.
79. San Francisco Department of Public Health, Lesbian & Gay
Substance Abuse Planning Group. Lesbian, Gay and Bisexual
Substance Abuse Needs Assessment. 1991, August;
80. Ascher MS, Sheppard HW, Winkelstein Jr W, Vittinghoff E. Does
drug use cause AIDS? Nature 1993; 362: 103-104.
81. Haverkos HW, Drotman DP. NIDA technical review: nitrite
inhalants. Biomedicine & Pharmacotherapy 1996; 50: 228-230.
82. Fietz M. Haschisch an der Spitze; SPD: Mildere Strafen fuer
Drogenhaendler. Die Welt 1997; pp. 1,2, Jan. 8.
83. Rauschgiftbilanz 1994. Starke Nachfrage nach synthetischen Drogen.
Deutsches Aerzteblatt 1995; 92: C-422.
84. AIDS-Forschung. AIDS Zentrum im Robert Koch Institut. 120.
Bericht des AIDS-Zentrums im Robert-Koch-Institut tiber aktuelle
epidemiologische Daten. AIDS-Forschung 1996; 11: 47-56.
85. U.S. Department of Health & Human Services. Annual emergency
department data 1993. Data from the Drug Abuse Warning Network
(DAWN) 1993; 81-110,
LÆKNANEMINN f 3Q 1 - tbl. 1997, 50. árg.